{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:25:38Z","timestamp":1787066738073,"version":"build-2736575974"},"reference-count":12,"publisher":"Society of Nuclear Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Nucl. Med.\n                Technol."],"accepted":{"date-parts":[[2026,7,7]]},"DOI":"10.2967\/jnmt.126.272633","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:52:40Z","timestamp":1787064760000},"page":"jnmt.126.272633","source":"Crossref","is-referenced-by-count":0,"title":["Radiation Exposure from Patients During\n                    <sup>177<\/sup>\n                    Lu-DOTATATE Infusions"],"prefix":"10.2967","author":[{"given":"Sameer V.","family":"Tipnis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Rieter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"2026081807350792000_jnmt.126.272633v1.1","unstructured":"Lutathera [product information]. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/208700s000lbl.pdf. Accessed July 28, 2026."},{"key":"2026081807350792000_jnmt.126.272633v1.2","unstructured":"Lutathera [product monograph]. https:\/\/pdf.hres.ca\/dpd_pm\/00049099.PDF. Published January 9, 2019. Accessed August 4, 2026."},{"key":"2026081807350792000_jnmt.126.272633v1.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427"},{"key":"2026081807350792000_jnmt.126.272633v1.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.2553"},{"key":"2026081807350792000_jnmt.126.272633v1.5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2743"},{"key":"2026081807350792000_jnmt.126.272633v1.6","unstructured":"U.S. Nuclear Regulatory Commission website. Proposed revision 2 to regulatory guide 8.39: release of patients administered radioactive material. https:\/\/www.nrc.gov\/docs\/ML2123\/ML21230A318.pdf. Accessed July 28, 2026."},{"key":"2026081807350792000_jnmt.126.272633v1.7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00411-017-0721-6","article-title":"Blood clearance and occupational exposure for 177Lu-DOTATATE compared to 177Lu-PSMA radionuclide therapy","volume":"57","author":"Abuqbeitah","year":"2018","journal-title":"Radiat Environ Biophys."},{"key":"2026081807350792000_jnmt.126.272633v1.8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40658-019-0243-1","article-title":"Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours","volume":"6","author":"Levart","year":"2019","journal-title":"EJNMMI Phys."},{"key":"2026081807350792000_jnmt.126.272633v1.9","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.7150\/ijms.58680","article-title":"Patient external dose rate after 177Lu-DOTATATE therapy: factors affecting its decrease and predictive value","volume":"18","author":"Zhang-Yin","year":"2021","journal-title":"Int J Med Sci."},{"key":"2026081807350792000_jnmt.126.272633v1.10","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/MNM.0000000000000232","article-title":"Quantifying public radiation exposure related to lutetium-177 octreotate therapy for the development of a safe outpatient treatment protocol","volume":"36","author":"Olmstead","year":"2015","journal-title":"Nucl Med Commun."},{"key":"2026081807350792000_jnmt.126.272633v1.11","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/HP.0000000000001122","article-title":"Radiation safety observations associated with 177Lu Dotatate patients","volume":"117","author":"Nelson","year":"2019","journal-title":"Health Phys."},{"key":"2026081807350792000_jnmt.126.272633v1.12","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12149-014-0843-8","article-title":"Radiation safety of outpatient 177Lu-octreotate radiopeptide therapy of neuroendocrine tumors","volume":"28","author":"Calais","year":"2014","journal-title":"Ann Nucl Med."}],"container-title":["Journal of Nuclear Medicine Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnmt.126.272633","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:52:43Z","timestamp":1787064763000},"score":1,"resource":{"primary":{"URL":"http:\/\/tech.snmjournals.org\/lookup\/doi\/10.2967\/jnmt.126.272633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":12,"alternative-id":["10.2967\/jnmt.126.272633"],"URL":"https:\/\/doi.org\/10.2967\/jnmt.126.272633","relation":{},"ISSN":["0091-4916","1535-5675"],"issn-type":[{"value":"0091-4916","type":"print"},{"value":"1535-5675","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]}}}